The immunophenotype was assessed by flow cytometry in the different collaborating study groups and was known in 132 out of 133 infants (99%). Ninety-two infant ALL cases (69%) showed the CD10 ...

The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

The treatment of leukemia among children could be made more precise with fewer side effects with the help of more accurate ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Jylamvo is now approved for pediatric acute lymphoblastic leukemia and juvenile idiopathic arthritis, offering a liquid methotrexate formulation. The formulation is stable at room temperature for 90 ...

The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in ...